Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5168770 | 1.00 | BACE1 (0.68) | BACE1CTSD | |
| SCHEMBL5171209 | 1.00 | BACE1 (0.68) | BACE1CTSD | |
| SCHEMBL5165788 | 0.88 | CTSD (0.57) | BACE1CTSD | |
| SCHEMBL6040138 | 0.86 | CTSD (0.72) | BACE1CTSD | |
| SCHEMBL5165919 | 0.86 | CTSD (0.72) | BACE1CTSD | |
| SCHEMBL5165929 | 0.86 | CTSD (0.72) | BACE1CTSD | |
| SCHEMBL14156803 | 0.83 | BACE1 (0.75) | BACE1CTSD | |
| SCHEMBL8276578 | 0.83 | BACE1 (0.75) | BACE1CTSD | |
| SCHEMBL4255935 | 0.83 | BACE1 (0.75) | BACE1CTSD | |
| SCHEMBL4255940 | 0.83 | BACE1 (0.75) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| EP-1773758-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ASPH, DNPEP, APP | BACE1 19/4885CTSD 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.